TARA vs. CRIS, CSBR, TSBX, GNTA, IKNA, LENZ, ENTX, CVM, ALGS, and DYAI
Should you be buying Protara Therapeutics stock or one of its competitors? The main competitors of Protara Therapeutics include Curis (CRIS), Champions Oncology (CSBR), Turnstone Biologics (TSBX), Genenta Science (GNTA), Ikena Oncology (IKNA), LENZ Therapeutics (LENZ), Entera Bio (ENTX), CEL-SCI (CVM), Aligos Therapeutics (ALGS), and Dyadic International (DYAI). These companies are all part of the "biological products, except diagnostic" industry.
Protara Therapeutics (NASDAQ:TARA) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, community ranking, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.
Protara Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.59, suggesting that its share price is 259% more volatile than the S&P 500.
Protara Therapeutics has higher earnings, but lower revenue than Curis. Curis is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Protara Therapeutics had 4 more articles in the media than Curis. MarketBeat recorded 6 mentions for Protara Therapeutics and 2 mentions for Curis. Curis' average media sentiment score of 1.89 beat Protara Therapeutics' score of 0.76 indicating that Curis is being referred to more favorably in the news media.
Protara Therapeutics presently has a consensus target price of $26.50, suggesting a potential upside of 870.70%. Curis has a consensus target price of $37.33, suggesting a potential upside of 230.68%. Given Protara Therapeutics' higher probable upside, equities analysts plainly believe Protara Therapeutics is more favorable than Curis.
38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 12.5% of Protara Therapeutics shares are owned by insiders. Comparatively, 5.7% of Curis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Curis received 657 more outperform votes than Protara Therapeutics when rated by MarketBeat users. Likewise, 67.65% of users gave Curis an outperform vote while only 63.27% of users gave Protara Therapeutics an outperform vote.
Protara Therapeutics has a net margin of 0.00% compared to Curis' net margin of -486.45%. Protara Therapeutics' return on equity of -58.80% beat Curis' return on equity.
Summary
Protara Therapeutics beats Curis on 10 of the 16 factors compared between the two stocks.
Get Protara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Protara Therapeutics Competitors List
Related Companies and Tools
